Intravenous Immunoglobulin

Immunoglobulins (IgG) for intravenous administration (IVIG) have different effects on the immune system.

During the first small studies that did not show multicenter study wide effectiveness convincing Australian found that the monthly management of low-dose IVIG effective and well tolerated. A group of patients 148 RRMS (EDSS 1-6) randomly into two groups, one treated with IVIG monthly dose of 0.15 to 0.20 kg / g split and the other received a placebo for two years. Was ultimately the main effects of treatment on clinical disability (as measured by the change in EDSS), and the proportion of patients who have debilitating disability, remained stable or deteriorating (difference of one point at least on EDSS). The analysis is based on the plan showed that IVIG therapy have a significant positive impact, albeit modest, in EDSS.